Article Information
- September 27, 2021.
Author Information
- Carlos Tornero1,2,
- Ernesto Pastor1,
- María del Mar Garzando1,
- Jorge Orduña1,
- MJ Forner3,
- Irene Bocigas4,
- David L. Cedeño5,6,
- Ricardo Vallejo5,6,
- Peter Staats7,* and
- Eric J. Liebler7
- 1Hospital Clínico Universitario de Valencia, Anesthesia, Critical Care and Pain Management Unit, Valencia, Spain
- 2Cátedra Dolor, UFV-Fundación Vithas, Madrid, Spain
- 3Hospital Clínico Universitario de Valencia, Internal Medicine Department, Valencia, Spain
- 4Hospital Clínico Universitario de Valencia, Pulmonary Department, Valencia, Spain
- 5Department of Basic Science, Millennium Pain Center, Bloomington, IL, USA
- 6Department of Psychology, Illinois Wesleyan University, Bloomington, IL, USA
- 7electroCore, Inc., Rockaway, NJ, USA
- ↵*Corresponding author:
Peter Staats, MD, 200 Forge Way, Suite 205, Rockaway, NJ 07866, Phone: 732-687-0351, Email: peter.staats{at}electrocore.com
Author contributions CT, EP, MdMG, JO, MJF, IB, DLC, RV, PS, and EJL contributed to conception and design of the study. CT, EP, MdMG, JO, MJF, and IB acquired the data. CT, EP, MdMG, JO, MJF, IB, DLC, RV, PS, and EJL participated in the analysis and interpretation of the data. All authors contributed to manuscript revision, read, and approved the submitted version and agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.
Contribution to the field: Severe coronavirus disease 2019 (COVID-19) is characterized, in part, by an excessive acute inflammatory response. Evidence from animal and human studies suggests that vagus nerve stimulation can lead to reduced levels of various pro-inflammatory cytokines. We hypothesized that non-invasive vagus nerve stimulation (nVNS) could inhibit the inflammatory signaling process indicative of COVID-19 progression and tested this hypothesis in the first prospective randomized controlled study of nVNS therapy in patients with COVID-19. The inflammatory biomarkers C-reactive protein and procalcitonin showed significantly greater reductions from baseline with nVNS therapy than with the standard of care. nVNS is easily deployable treatment modality with a well-established safety and tolerability profile and has multiple mechanisms of action that may be relevant to COVID-19. The potential benefits of its use in this capacity should be further studied.
